Premium
Long‐term survivor of relapsed stage IV malignant rhabdoid tumor of the kidney
Author(s) -
Kato Motohiro,
Koh Katsuyoshi,
Oshima Koichi,
Oguma Eiji,
Uchida Hiroo,
Kishimoto Hiroshi,
Kikuchi Akira,
Hanada Ryoji
Publication year - 2013
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2012.03663.x
Subject(s) - medicine , pirarubicin , thiotepa , ifosfamide , carboplatin , etoposide , melphalan , chemotherapy , stage (stratigraphy) , vincristine , doxorubicin , surgery , anthracycline , urology , oncology , cancer , cyclophosphamide , cisplatin , breast cancer , paleontology , biology
The prognosis for metastatic malignant rhabdoid tumor (MRT) is poor, and metastatic (stage IV) MRT was resistant to conventional treatment, with less than 20% of cure rate. Moreover, there have been no reports of patients who have survived relapsed stage IV MRT. Here we report a long‐term survivor of relapsed MRT with lung metastasis at diagnosis. He was diagnosed as MRT of the kidney at 5‐month‐old. After resection of the renal tumor, he was treated with ICE (ifosfamide, carboplatin, and etoposide), total abdominal irradiation 10.8Gy and high‐dose chemotherapy using thiotepa and melphalan. Six months after initial treatment, a relapse in the lung was detected, and he received chemotherapy including doxorubicin/pirarubicin for 78 weeks. He is alive at five years of follow up, without any evidence of disease. Our report suggests the important role of anthracycline in treatment of MRT.